Initial public offer of up to 61,78,800 equity shares of face value of Rs. 10/- each ("Equity shares") of Mahamaya Lifesciences Limited ("MLL" or the "Company") for cash at price of Rs. 114 per equity share (including a share premium of Rs.94 per equity share) (the "Offer Price"), aggregating up to Rs. 70.44 Crore ("the Offer"), comprising a fresh offer of upto 56,38,800* equity shares aggregating to Rs. 64.28 Crore (the "Fresh Offer") and an offer for sale of upto 540,000* equity shares (the "Offered Shares") of face value of Rs. 10/- each aggregating up to Rs. 6.16 Crore ("offer for sale") comprising of 3,70,000* equity shares aggregating up to Rs. 4.22 Crore by Krishnamurthy Ganesan and 1,70,000* equity shares aggregating up to Rs. 1.94 Crore by Lalitha Krishnamurthy (collectively reffered to as the "Selling Shareholders") out of which 3,09,600 equity shares of face value Rs. 10/- each, at an offer price of Rs. 114 per equity share for cash, aggregating Rs. 3.53 crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The offer less market maker reservation portion i.e. net offer of 58,69,200* equity shares of face value of Rs. 10/- each, at an offer price of Rs. 114 per equity share for cash, aggregating up to Rs. 66.91 crores is hereinafter referred to as the "Net Offer". The offer and net offer will constitute 26.40% and 25.08% respectively of the post-offer paid-up equity share capital of the company.